Ensign Peak Advisors, Inc Innoviva, Inc. Transaction History

Ensign Peak Advisors, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$11.61 - $15.22 $63,971 - $83,862	-5,510 Reduced 16.25%	28,391 $330,000
Q4 2021 Feb 11, 2022	SELL	$15.91 - $18.72 $827,320 - $973,439	-52,000 Reduced 60.53%	33,901 $585,000
Q2 2021 Aug 13, 2021	BUY	$11.45 - $13.96 $153,430 - $187,064	13,400 Added 18.48%	85,901 $1.15 Million
Q1 2021 May 12, 2021	BUY	$11.06 - $12.87 $108,388 - $126,125	9,800 Added 15.63%	72,501 $866,000
Q4 2020 Feb 12, 2021	SELL	$9.33 - $12.48 $139,950 - $187,200	-15,000 Reduced 19.3%	62,701 $777,000
Q4 2019 Feb 14, 2020	BUY	$10.28 - $14.38 $798,766 - $1.12 Million	77,701 New	77,701 $1.1 Million

229

79.2M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.33B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.